Opinion on Pharmaceutical Manufacturers

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Bayer/GSK: Levitra approved by FDA

The success of the erectile dysfunction drug Levitra is crucial for Bayer's [BAY.F] short-term future, as the company has little else in the pipeline to provide growth potential. For GSK [GSK.L], although less vital for survival, the success of this drug launch is also of key importance.

Published By Datamonitor
20 Aug 2003
CommentWire
CommentWire

Plant vaccines: growing closer to commercial reality

Transgenic plant technologies could lead to a revolution in vaccine production and manufacture. Should plant-based vaccines prove effective in clinical trials, this will drive licensing activity between key vaccine players and companies with relevant intellectual property.

Published By Datamonitor
20 Aug 2003
CommentWire
CommentWire

Schering-Plough: cancer can cure its woes

Schering-Plough [SGP] faces increasing competition in markets it used to dominate, such as hepatitis C and allergic rhinitis. The company has attempted to reverse this trend by moving into alternative franchises such as oncology. Schering-Plough may seek to complement its organic growth by partnering with a company that has expertise in this area.<BR />

Published By Datamonitor
27 Aug 2003
CommentWire
CommentWire

Johnson & Johnson: fat figures and slimmer waistlines

Recent evidence has shown that Johnson & Johnson's [JNJ] Topamax promotes weight loss in obese patients with type II diabetes. The drug is currently used to treat epilepsy although it has shown potential for a number of indications in clinical studies. The company hopes to boost Topamax sales further by penetrating a difficult but potentially lucrative market.<BR />

Published By Datamonitor
29 Aug 2003
CommentWire
CommentWire

AstraZeneca: positive new data for Exanta and Atacand

Findings from three large-scale trials support the use of AstraZeneca's [AZN.L] new oral direct thrombin inhibitor, Exanta (ximelagatran), in post-MI and atrial fibrillation and the use of the angiotensin receptor blocker, Atacand (candesartan), in patients with heart failure. These results will further the company's stated aim to become the major cardiovascular player within the next five years.

Published By Datamonitor
04 Sep 2003
CommentWire
CommentWire

Antibiotics: use drops among US children

A new study has reported a substantial decrease in pediatric antibiotic prescriptions between 1996 and 2000. The development shows the success of a wider campaign to reduce overuse of antibiotics - a serious problem that contributes to the development of disease-resistant forms of common bacteria.

Published By Datamonitor
04 Sep 2003
CommentWire
CommentWire

Ulcer drugs: challenges in store

Procter & Gamble's [PG] launch of Prilosec OTC will have wide-ranging effects on the market for heartburn and ulcer drugs. The availability of an OTC alternative is leading US insurance companies to restrict access to competing prescription drugs. Although generic OTC omeprazole will not be available for several years, PPI companies must find successor products to protect their franchises.

Published By Datamonitor
22 Sep 2003
CommentWire
CommentWire

Pancreatic cancer: vaccine gives new hope

Researchers at the Memorial Sloan-Kettering Cancer Center in the US have reported promising results for a pancreatic cancer vaccine developed using proteins from the patient's own tumor. Although preliminary results appear encouraging, it will be some time before patients can gain access to the drug.

Published By Datamonitor
23 Sep 2003
CommentWire
CommentWire

Novartis: Prexige delay proving painful

The FDA has requested the submission of Novartis' [NVS] TARGET study report as well as additional clinical data for COX-II inhibitor Prexige. Delayed entry into the already saturated COX-II inhibitor market is bad news for the Swiss company, which hopes to capture market share from leaders Pfizer [PFZ.L] and Merck & Co [MRK].

Published By Datamonitor
29 Sep 2003
CommentWire
CommentWire

Bayer: too little, too late?

Bayer's [BAY.F] company structure has been modernized, with its conglomerate model streamlined to allow its four major components the freedom to operate independently and undergo M&A. However, the Healthcare division's portfolio is such that it may have trouble even finding a potential merger partner.

Published By Datamonitor
01 Oct 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.